Tumour-infiltrating Gr-1+ myeloid cells antagonize senescence in cancer
Open accessThe DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
Aberrant activation of oncogenes or loss of tumour suppressor genes opposes malignant transformation by triggering a stable arrest in cell growth, which is termed cellular senescence. This process is finely tuned by both cell-autonomous and non-cell-autonomous mechanisms that regulate the entry of tumour cells to senescence. Whether tumour-infiltrating immune cells can oppose senescence is unknown. Here we show that at the onset of senescence, PTEN null prostate tumours in mice are massively infiltrated by a population of CD11b(+)Gr-1(+) myeloid cells that protect a fraction of proliferating tumour cells from senescence, thus sustaining tumour growth. Mechanistically, we found that Gr-1(+) cells antagonize senescence in a paracrine manner by interfering with the senescence-associated secretory phenotype of the tumour through the secretion of interleukin-1 receptor antagonist (IL-1RA). Strikingly, Pten-loss-induced cellular senescence was enhanced in vivo when Il1ra knockout myeloid cells were adoptively transferred to PTEN null mice. Therapeutically, docetaxel-induced senescence and efficacy were higher in PTEN null tumours when the percentage of tumour-infiltrating CD11b(+)Gr-1(+) myeloid cells was reduced using an antagonist of CXC chemokine receptor 2 (CXCR2). Taken together, our findings identify a novel non-cell-autonomous network, established by innate immunity, that controls senescence evasion and chemoresistance. Targeting this network provides novel opportunities for…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“By contrast, during cancer development associated with accumulation of senescent cells, SASP can recruit immature myeloid cells to promote tumorigenesis in a paracrine manner160,161.”
From Cellular senescence in ageing: from mechanisms to therapeutic opportunities (2021) · cites this paper as [160]
In the citing paper
“Further, the SASP can recruit immature immune-suppressive myeloid cells to prostate and liver tumors (Di Mitri et al., 2014; Eggert et al., 2016) and stimulate tumorigenesis by driving angiogenesis and metastasis (Coppe ´ et al., 2010).”
From Cellular Senescence: Defining a Path Forward (2019) · cites this paper as Di Mitri et al., 2014
In the citing paper
“In some instances, the SASP can also have immunosuppressive functions (Di Mitri et al. 2014; Eggert et al. 2016).”
From Senescence and the SASP: many therapeutic avenues (2020) · cites this paper as Di Mitri et al. 2014
In the citing paper
“Notably, data from various mouse models indicate that disrupting the CXCR1/2–MDSC axis in tumours is therapeutically efficacious across a wide variety of solid cancers166–172.”
From The current state of the art and future trends in RAS-targeted cancer therapies (2022) · cites this paper as [167]
In the citing paper
“There is convergent evidence that this occurs via the recruitment of myeloid-derived suppressor cells (MDSCs) chemoattracted by factors (e.g., IL-6, IL-8, and CCL2) secreted by senescent cells in murine models of HCC, 193 prostate, 194 and skin cancers.195”
From Meta-hallmarks of aging and cancer (2023) · cites this paper as [194]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
The cancer genome atlas pan-cancer analysis project
The Cancer Genome Atlas Research Network, Weinstein, J. N., Collisson, E. A., Mills, G. B., Shaw, K. R. M., Ozenberger, B. A., Ellrott, K., Shmulevich, I., Sander, C., & Stuart, J. M. (2013) · Nature Genetics · doi:10.1038/ng.2764 · Cited by 9,092
Myeloid-derived-suppressor cells as regulators of the immune system
Gabrilovich, D. I., & Nagaraj, S. (2009) · Nature Reviews Immunology · doi:10.1038/nri2506 · Cited by 6,753
Coordinated regulation of myeloid cells by tumours
Gabrilovich, D. I., Ostrand-Rosenberg, S., & Bronte, V. (2012) · Nature Reviews Immunology · doi:10.1038/nri3175 · Cited by 3,544
Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas
Xue, W., Zender, L., Miething, C., Dickins, R. A., Hernando, E., Krizhanovsky, V., Cordon-Cardo, C., & Lowe, S. W. (2007) · Nature · doi:10.1038/nature05529 · Cited by 2,473
A complex secretory program orchestrated by the inflammasome controls paracrine senescence
Acosta, J. C., Banito, A., Wuestefeld, T., Georgilis, A., Janich, P., Morton, J. P., Athineos, D., Kang, T.-W., Lasitschka, F., Andrulis, M., et al. (2013) · Nature Cell Biology · doi:10.1038/ncb2784 · Cited by 2,278
Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis
Chen, Z., Trotman, L. C., Shaffer, D., Lin, H.-K., Dotan, Z. A., Niki, M., Koutcher, J. A., Scher, H. I., Ludwig, T., Gerald, W., et al. (2005) · Nature · doi:10.1038/nature03918 · Cited by 1,993
Senescence surveillance of pre-malignant hepatocytes limits liver cancer development
Kang, T.-W., Yevsa, T., Woller, N., Hoenicke, L., Wuestefeld, T., Dauch, D., Hohmeyer, A., Gereke, M., Rudalska, R., Potapova, A., et al. (2011) · Nature · doi:10.1038/nature10599 · Cited by 1,621
Senescence in premalignant tumours
Collado, M., Gil, J., Efeyan, A., Guerra, C., Schuhmacher, A. J., Barradas, M., Benguría, A., Zaballos, A., Flores, J. M., Barbacid, M., et al. (2005) · Nature · doi:10.1038/436642a · Cited by 1,482
Self-citationOncogene-induced senescence as an initial barrier in lymphoma development
Braig, M., Lee, S., Loddenkemper, C., Rudolph, C., Peters, A. H. F. M., Schlegelberger, B., Stein, H., Dörken, B., Jenuwein, T., & Schmitt, C. A. (2005) · Nature · doi:10.1038/nature03841 · Cited by 1,220
Senescence in tumours: evidence from mice and humans
Collado, M., & Serrano, M. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2772 · Cited by 1,124
Self-citation
Cited by
Items 201–300 of 409
Ullah, A., Chen, Y., Singla, R. K., Cao, D., & Shen, B. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107213 · Cited by 32
Toso, A., Mitri, D. D., & Alimonti, A. (2015) · OncoImmunology · doi:10.4161/2162402x.2014.994380 · Cited by 35
“Ptenpc¡/¡ mice have been shown to be irresponsiveness to the chemotherapeutic agent Docetaxel.(10) In Ptenpc¡/¡ mice treated with Docetaxel we found an enhanced senescence response and increased phosphorylation of Stat3 that resulted in activation of the negative SASP of Ptenpc¡/¡ tumors.”
BackgroundSelf-citationIn Brief: Myeloid‐derived suppressor cells in cancer
Solito, S., Pinton, L., & Mandruzzato, S. (2017) · The Journal of Pathology · doi:10.1002/path.4876 · Cited by 30
In Vivo Imaging Sheds Light on Immune Cell Migration and Function in Cancer
Torcellan, T., Stolp, J., & Chtanova, T. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00309 · Cited by 32
Sun, H.-W., Chen, J., Wu, W., Yang, Y., Xu, Y.-T., Yu, X.-J., Chen, H., Wang, Z., Wu, X., & Zheng, L. (2021) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-20-0389 · Cited by 30
“MDSCs are key regulators of antitumor immunity and affect virtually all types of cancer therapy (13, 14, 54).”
BackgroundSelf-citationMyeloid-derived suppressor cells and their role in gynecological malignancies
Mabuchi, S., Yokoi, E., Komura, N., & Kimura, T. (2018) · Tumor Biology · doi:10.1177/1010428318776485 · Cited by 29
“Moreover, circulating MDSC were found to predict worse responses to cytotoxic chemotherapeutic agents.(4,26,27) In a study of breast cancer that were treated with neo-adjuvant chemotherapy, although the difference was not statistically significant, the number of circulating PMN-MDSC at the end of chemotherapy was lowe…”
BackgroundCombined Effects of Myeloid Cells in the Neuroblastoma Tumor Microenvironment
Frosch, J., Leontari, I., & Anderson, J. (2021) · Cancers · doi:10.3390/cancers13071743 · Cited by 29
Chen, Z., Yuan, R., Hu, S., Yuan, W., & Sun, Z. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.817942 · Cited by 30
Myeloid-derived suppressor cells in cancer: Current knowledge and future perspectives
Rajkumari, S., Singh, J., Agrawal, U., & Agrawal, S. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.112949 · Cited by 28
CXCL7-induced macrophage infiltration in lung tumor is independent of CXCR2 expression
Ünver, N., Esendağlı, G., Yılmaz, G., & Güç, D. (2015) · Cytokine · doi:10.1016/j.cyto.2015.07.018 · Cited by 29
Epigenetic Suppression of SERPINB1 Promotes Inflammation-Mediated Prostate Cancer Progression
Lerman, I., Ma, X., Seger, C., Maolake, A., García-Hernández, M. D. L. L., Rangel‐Moreno, J., Ackerman, J. E., Nastiuk, K. L., Susiarjo, M., & Hammes, S. R. (2019) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-18-0638 · Cited by 28
Myeloid-Derived Suppressor Cells: Facilitators of Cancer and Obesity-Induced Cancer
Ostrand‐Rosenberg, S. (2020) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-042120-105240 · Cited by 27
“MDSC promote tumor growth by protecting tumor cells from senescence by secreting the IL-1 receptor antagonist, which blocks the production of prosenescence factors (Di Mitri et al. 2014).”
BackgroundImpact of cancer cell-intrinsic features on neutrophil behavior
Duits, D. E. M., & de Visser, K. E. (2021) · Seminars in Immunology · doi:10.1016/j.smim.2021.101546 · Cited by 27
Senescent neutrophils: a hidden role in cancer progression
Rys, R. N., & Calcinotto, A. (2024) · Trends in Cell Biology · doi:10.1016/j.tcb.2024.09.001 · Cited by 28
IL-36γ armored CAR T cells reprogram neutrophils to induce endogenous antitumor immunity
Zuo, Y.-H., Vohwinkel, D. J., Dong, B., McDowell, J. R., Guzman, B. V., Pandian, T. S. M., Chattopadhyay, S., McGray, A. R., Olejniczak, S. H., Ohm, J. E., et al. (2025) · Cancer Cell · doi:10.1016/j.ccell.2025.11.007 · Cited by 26
Proteomic and transcriptomic profiling of Pten gene‐knockout mouse model of prostate cancer
Zhang, J., Kim, S., Li, L., Kemp, C. J., Jiang, C., & Lü, J. (2020) · The Prostate · doi:10.1002/pros.23972 · Cited by 26
Arora, S., Khan, S. F., Zaki, A., Tabassum, G., Mohsin, M., Bhutto, H. N., Ahmad, T., Fatma, T., & Syed, M. A. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.03.002 · Cited by 30
Rodríguez-Agustín, A., Casanova, V., Grau-Expósito, J., Sánchez‐Palomino, S., Alcamí, J., & Climent, N. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15030917 · Cited by 28
“Additional mechanisms of NK-cell resistance include the SASP-mediated recruitment of CCR2+ immature myeloid cells (iMC), which inhibit NK-cell inhibition in established tumors, thus further contributing to tumor growth [147,148].”
BackgroundKalathil, A. A., Guin, S., Ashokan, A., Basu, U., Surnar, B., Delma, K. S., Lima, L. M., Kryvenko, O., & Dhar, S. (2023) · ACS Central Science · doi:10.1021/acscentsci.3c00286 · Cited by 21
Interleukin-1 receptor antagonist: An alternative therapy for cancer treatment
Zhang, F., Jiang, J., & Zheng, X. W. (2023) · Life Sciences · doi:10.1016/j.lfs.2023.122276 · Cited by 25
Pharmacological Modulation of Proton Channel Hv1 in Cancer Therapy: Future Perspectives
Fernández, A., Pupo, A., Mena‐Ulecia, K., & Gonzalez, C. L. (2016) · Molecular Pharmacology · doi:10.1124/mol.116.103804 · Cited by 26
Šímová, J., Sapega, O., Hornofova, T., Štěpánek, I., Kyjacová, L., Mikyšková, R., Indrová, M., Bieblová, J., Bubenik, J., Bártek, J., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.10712 · Cited by 27
“com/oncotarget for various types of human malignancies, has been previously shown to induce massive cellular senescence in several tumor cell lines [23, 25].”
BackgroundThe impact of the senescent microenvironment on tumorigenesis: Insights for cancer therapy
Zhang, W., Zhang, K., Shi, J., Qiu, H., Kan, C., Ma, Y., Hou, N., Han, F., & Sun, X. (2024) · Aging Cell · doi:10.1111/acel.14182 · Cited by 24
Lopez, M. F., Niu, P., Wang, L., Vogelsang, M. S., Gaur, M., Krastins, B., Zhao, Y., Smagul, A., Nussupbekova, A., Akanov, A. A., et al. (2017) · npj Aging and Mechanisms of Disease · doi:10.1038/s41514-017-0006-y · Cited by 25
Liu, Y., Liu, M., Wen, Y., Li, C., Yeh, H.-L., Dung, P. V. T., Jiang, K.-C., Chen, W.-H., Li, H.-R., Huang, J., et al. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.217090 · Cited by 22
Sun, X., Chen, Q., Zhang, L., Chen, J., & Zhang, X. (2021) · Mathematical Biosciences & Engineering · doi:10.3934/mbe.2021313 · Cited by 22
Self-citationIdentification of senescence-related molecular subtypes and key genes for prostate cancer
Feng, D., Zhu, W., Shi, X., Xiong, Q., You, J., Wei, Q., & Yang, L. (2022) · Asian Journal of Andrology · doi:10.4103/aja202258 · Cited by 23
Coagulation factor X promotes resistance to androgen-deprivation therapy in prostate cancer
Calì, B., Troiani, M., Bressan, S., Attanasio, G., Merler, S., Moscarda, V., Mosole, S., Ricci, E. D., Guo, C. W., Yuan, W., et al. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.08.018 · Cited by 24
Self-citationJinna, N., Rida, P. C. G., Su, T., Gong, Z., Yao, S., LaBarge, M. A., Natarajan, R. D., Jovanović‐Talisman, T., Ambrosone, C. B., & Seewaldt, V. L. (2022) · Cells · doi:10.3390/cells11233818 · Cited by 22
“These recruited MDSCs to block CD8+ T cell response via releasing IL-1 receptor antagonists that interfere with IL-1 signaling in tumor cells [90].”
BackgroundJiang, C., Song, Y., Rorive, S., Allard, J., Tika, E., Zahedi, Z., Dubois, C., Salmon, I. J., Sifrim, A., & Blanpain, C. (2025) · Nature Cancer · doi:10.1038/s43018-025-00994-3 · Cited by 21
Mehra, N., Sharp, A., Lorente, D., Dolling, D. I., Sumanasuriya, S., Johnson, B., Dearnaley, D. P., Parker, C. C., & Bono, J. S. D. (2017) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2017.05.012 · Cited by 21
Zhang, L., Hu, Y., Chen, W., Tian, Y., Xie, Y., & Chen, J. (2020) · Journal of Neuro-Oncology · doi:10.1007/s11060-020-03477-w · Cited by 20
Self-citationChen, J., Wang, Z., Ding, Y., Huang, F., Huang, W., Lan, R., Chen, R., Wu, B., Fu, L., Yang, Y., et al. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00004 · Cited by 22
“In fact, several agents have been found to reduce the proliferation of MDSCs or to target MDSCs’ trafficking in mouse and human tumors, for example, the inhibitor of CXCR2 (43), the CXCR4 antagonist AMD3100 (44), and the chemotherapeutic drugs doxorubicin (45), sunitinib (tyrosine kinase inhibitor) (46), and Avastin (…”
BackgroundSelf-citationNeutrophils in cancer: At the crucial crossroads of anti‐tumor and pro‐tumor
Cai, W., Fan, T. T., Xiao, C., Deng, Z., Liu, Y., Li, C., & He, J. (2025) · 癌症:英文版 · doi:10.1002/cac2.70027 · Cited by 23
Morgan, M. P., Finnegan, E., & Das, S. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.10.002 · Cited by 21
Methodological aspects of the molecular and histological study of prostate cancer: Focus on PTEN
Ugalde‐Olano, A., Egia, A., Fernández‐Ruiz, S., Loizaga‐Iriarte, A., Zúñiga-García, P., Garcia, S., Royo, F., Lacasa-Viscasillas, I., Castro, E., Cortázar, A. R., et al. (2015) · Methods · doi:10.1016/j.ymeth.2015.02.005 · Cited by 19
Fukuokaya, W., Kimura, T., Onuma, H., Mori, K., Honda, M., Inaba, H., Sasaki, H., Shimomura, T., Miki, K., & Egawa, S. (2019) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2019.04.010 · Cited by 19
Zheng, Z., Xu, Y., Shi, Y., & Shao, C. (2022) · Cellular Immunology · doi:10.1016/j.cellimm.2022.104576 · Cited by 18
Álvarez-Arzola, R., Oliver, L., Valdés, A. F.-C., & Mesa, C. (2018) · Seminars in Oncology · doi:10.1053/j.seminoncol.2018.05.001 · Cited by 18
Sapega, O., Mikyškov�, R., Bieblov�, J., Mrázková, B., Hodn�, Z., & Reiniš, M. (2018) · International Journal of Oncology · doi:10.3892/ijo.2018.4553 · Cited by 21
“DTX has already been described to induce cellular senescence in several tumour cell lines in a limited number of studies (38,39).”
Microbial-induced trained immunity for cancer immunotherapy
Vuscan, P., Kischkel, B., Joosten, L. A. B., & Netea, M. G. (2025) · Pharmacological Reviews · doi:10.1016/j.pharmr.2025.100074 · Cited by 19
FOXO3 Deficiency in Neutrophils Drives Colonic Inflammation and Tumorigenesis
Ghimire, J., Iftikhar, R., Penrose, H. M., Snarski, P., Ruiz, E. M., & Savkovic, S. D. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24119730 · Cited by 17
Dormancy of cutaneous melanoma
Singvogel, K., & Schittek, B. (2024) · Cancer Cell International · doi:10.1186/s12935-024-03278-5 · Cited by 17
Deng, T., Jiang, X., Zhao, Z., Zhao, X., Bi, A., Ouyang, S., Sun, S., Qiu, S., Fan, M., Xue, Q., et al. (2025) · Immunity · doi:10.1016/j.immuni.2025.06.011 · Cited by 17
Neutrophil Dynamics in Response to Cancer Therapies
Xu, H., Chen, X., Lu, Y., Sun, N., Weisgerber, K. E., Xu, M., & Bai, R.-Y. (2025) · Cancers · doi:10.3390/cancers17152593 · Cited by 18
“TANs also release interleukin-1 receptor antagonists (IL-1RA) to shield tumor cells from entering senescence, sustaining tumor proliferation [62].”
Plac1 Is a Key Regulator of the Inflammatory Response and Immune Tolerance In Mammary Tumorigenesis
Yuan, H., Wang, X., Shi, C., Jin, L., Hu, J., Zhang, A., Li, J., Vijayendra, N., Doodala, V., Weiss, S., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-24022-w · Cited by 19
Ni, T., Wang, H., Zhan, D., Li, T., Lv, M., Wang, W., Chu, Z., Zhou, Z., Sunagawa, M., & Liu, Y. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.119021 · Cited by 17
Differential Targeting of Gr-MDSCs, T Cells and Prostate Cancer Cells by Dactolisib and Dasatinib
Liu, G., Jin, Z., & Lü, X. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21072337 · Cited by 18
Han, Y., Micklem, G., & Kim, S. Y. (2023) · Ageing Research Reviews · doi:10.1016/j.arr.2023.101849 · Cited by 19
“…is further complicated by various factors, including its seemingly contradictory role in the immune milieu, where it has been reported to recruit immune-suppressive myeloid cells (Di Mitri et al., 2014; Eggert et al., 2016) but also contribute to chronic inflammation (Franceschi and Campisi, 2014).”
BackgroundRoles of Interleukin-1 Receptor Antagonist in Prostate Cancer Progression
Fan, Y.-C., Lee, K., & Tsai, Y.-C. (2020) · Biomedicines · doi:10.3390/biomedicines8120602 · Cited by 16
“It was reported that the IL1RN increased the proliferation of prostate epithelial cells [12]; also, the IL1RN was shown to antagonize oncogene-induced senescence in a Pten-null prostate cancer model [13] and was involved in the growth of pancreatic intraepithelial neoplasias in a Kras-G12D-mutant pancreatic cancer mod…”
BackgroundMethodMechanisms of Leydig Cell Aging and Obesity-Related Hypogonadism in Men: A Review
Huang, X., Zhao, H., Wu, X., Liang, Y., Guan, Q., Luo, D., & Yu, C. (2025) · Medical Science Monitor · doi:10.12659/msm.948180 · Cited by 17
“SASP has pro-inflammatory effects and promotes tumor development [26], and it also interacts with the immune response [27].”
Lessons from Hippocrates: Time to Change the Cancer Paradigm
Galmarini, C. M. (2020) · International Journal of Chronic Diseases · doi:10.1155/2020/4715426 · Cited by 17
“N2 neutrophils also suppress antitumor immune response by the release of inducible nitric oxide synthase (iNOS), arginase 1, or TGFβ [94, 95].”
BackgroundInvestigating Radiotherapy Response in a Novel Syngeneic Model of Prostate Cancer
Haughey, C. M., Mukherjee, D., Steele, R. E., Popple, A. L., Dura-Perez, L., Pickard, A., Patel, M., Jain, S., Mullan, P. B., Williams, R. D., et al. (2020) · Cancers · doi:10.3390/cancers12102804 · Cited by 16
“High numbers of MDSCs in a Pten−/− setting provide a protective effect on PCa cells from senescence, therefore sustaining tumour growth [13,38].”
BackgroundCellular Senescence, a Novel Area of Investigation for Metastatic Diseases
Faggioli, F., Velarde, M. C., & Wiley, C. D. (2023) · Cells · doi:10.3390/cells12060860 · Cited by 16
Johnson, B. (2023) · Cancers · doi:10.3390/cancers15225484 · Cited by 14
Liu, Y., Deng, Y., Yang, C., & Naranmandura, H. (2024) · Bioengineering · doi:10.3390/bioengineering11111084 · Cited by 17
Multifaceted roles of neutrophils in tumor microenvironment
Pan, X., Wang, Q., & Sun, B. (2024) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2024.189231 · Cited by 15
Chromatin-Associated Protein SIN3B Prevents Prostate Cancer Progression by Inducing Senescence
Bainor, A. J., Deng, F., Wang, Y., Lee, P., Cantor, D. J., Logan, S. K., & David, G. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-3410 · Cited by 14
“However, while we observed a modest, but non-significant increase in total prostate infiltrating CD45+ immune cells, as well as a significant increase in GR1-high, CD11B+ cells in Sin3b Pten compared to Sin3b prostates consistent with previous reports (22), we did not observe differences in immune cell infiltration be…”
BackgroundResultFundamental Principles of Cancer Biology: Does It Have Relevance to the Perioperative Period?
Li, J., Nick, A. M., & Sood, A. K. (2015) · Current anesthesiology reports · doi:10.1007/s40140-015-0122-9 · Cited by 15
“MDSCs are a variety of partially differentiated myeloid progenitors that have been identified in tumors, which have been shown to antagonize tumor senescence and suppress CTL activity [26, 27].”
BackgroundZhang, K., Chen, C., Liu, Y., Chen, H., & Liu, J. (2014) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/1440-1681.12328 · Cited by 16
Monocytes promote liver carcinogenesis in an oncogene-specific manner
Juric, V., Ruffell, B., Evason, K. J., Hu, J., Che, L., Wang, L., Chen, X., & Bishop, J. M. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.11.025 · Cited by 14
“[49] Di Mitri D, Toso A, Chen JJ, Sarti M, Pinton S, Jost TR, et al.”
BackgroundSenescence controls prostatic neoplasia driven by Pten loss
Parisotto, M., Grelet, É., Bizri, R. E., & METZGER, D. (2018) · Molecular & Cellular Oncology · doi:10.1080/23723556.2018.1511205 · Cited by 14
“It was proposed that interleukin-1 receptor antagonist (Il-1ra) secreted by infiltrated Gr-1 positive myeloid cells promotes the proliferation of some Pten-deficient prostatic epithelial cells, leading to PIN formation.(5) To further characterize the impact of Pten loss in prostatic epithelial cells of the mature pros…”
BackgroundInjectable Senolytic Hydrogel Depot for the Clearance of Senescent Cells
Paganella, L. G., Bovone, G., Cuni, F., Labouesse, C., Cui, Y., Giampietro, C., & Tibbitt, M. W. (2025) · Biomacromolecules · doi:10.1021/acs.biomac.4c00851 · Cited by 14
Nagatani, Y., Funakoshi, Y., Suto, H., Imamura, Y., Toyoda, M., Kiyota, N., Yamashita, K., & Minami, H. (2021) · Journal of Cancer Research and Therapeutics · doi:10.4103/jcrt.jcrt_1222_20 · Cited by 15
Senotherapeutics: An emerging approach to the treatment of viral infectious diseases in the elderly
Li, Z., Tian, M., Wang, G., Cui, X., Ma, J., Liu, S., Shen, B., Liu, F., Wu, K., Xiao, X., et al. (2023) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2023.1098712 · Cited by 15
Fan, Y.-C., Fong, Y.-C., Kuo, C., Li, C.-W., Chen, W., Lin, J.-D., Bürtin, F., Linnebacher, M., Bui, Q. T., Lee, K., et al. (2023) · Cell & Bioscience · doi:10.1186/s13578-023-01090-8 · Cited by 15
“As discussed previously, IL-1Ra can assist tumor progression through multiple mechanisms; thus, IL-1Ra induction contributes to the tumor-promoting effect of inflammation [59, 60].”
BackgroundDuctal activation of oncogenic KRAS alone induces sarcomatoid phenotype
Fu, Y., Cruz‐Monserrate, Z., Lin, H. H., Chung, Y., Ji, B., Lin, S.-M., Vonderfecht, S. L., Logsdon, C. D., Li, C., & Ann, D. K. (2015) · Scientific Reports · doi:10.1038/srep13347 · Cited by 13
“Rabbit anti-elastase I polyclonal antibody was from Life Span BioSciences, Inc. Biotin rat anti-mouse CD45 (53078), rat anti-mouse Ly-6G and Ly-6C (Gr-1) (550291) were from BD Biosciences and anti-mouse F4/80 (14-4801) was from eBioscience.”
MethodInfluentialCellular senescence: Silent operator and therapeutic target in cancer
Ramu, D., Teoh, W. S., Hirpara, J. L., & Pervaiz, S. (2021) · IUBMB Life · doi:10.1002/iub.2460 · Cited by 13
“In a separate study, the presence of myeloid cells within the tumor was shown to enhance the growth of prostate cancer by inhibiting senescence.(119) MDSCs mediate senescence mechanism in prostate cancer cells by releasing IL-1 receptor antagonist (IL-1RA) into the tumor microenvironment.”
Background[Delayed endolymphatic hydrops].
Giannoni, B., Pagnini, P., & Vannucchi, P. (1998) · PubMed · Cited by 13
Wang, Z., Chen, C., Ai, J., Gao, Y., Wang, L., Xia, S., Jia, Y., & Qin, Y. (2025) · MedComm · doi:10.1002/mco2.70048 · Cited by 18
Bacca, L. F. G., Brandariz, J., Zacchi, F., Zivi, A., Mateo, J., & Labbé, D. P. (2025) · Gene · doi:10.1016/j.gene.2025.149774 · Cited by 16
Yang, X., Yu, Y., Wang, Z., Wu, P., Su, X., Wu, Z., Gan, J., & Zhang, D. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.968043 · Cited by 14
“MDSCs are immunosuppressive cells that can directly promote the formation of tumor stem cells and protect proliferating tumor cells from apoptosis (84, 85).”
BackgroundZhu, Q., Chai, Y., Jin, L., Ma, Y., Lü, H., Chen, Y., & Wei, F. (2023) · Scientific Reports · doi:10.1038/s41598-023-45289-8 · Cited by 13
Ziglari, T., Calistri, N. L., Finan, J. M., Derrick, D. S., Nakayasu, E. S., Burnet, M. C., Kyle, J. E., Hoare, M., Heiser, L. M., & Pucci, F. (2025) · Cancer Research · doi:10.1158/0008-5472.can-24-0875 · Cited by 11
mtDNA transfer from senescent cancer cells to MDSCs promotes immunosuppression
Cañadas, I., Murayama, T., & Galluzzi, L. (2025) · Trends in cancer · doi:10.1016/j.trecan.2025.06.010 · Cited by 11
Brown, J. S. (2016) · Schizophrenia Bulletin · doi:10.1093/schbul/sbw064 · Cited by 11
Myeloid-Derived Suppressor Cells and Pulmonary Hypertension
Bryant, A. J., Mehrad, B., Brusko, T. M., West, J. D., & Moldawer, L. L. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19082277 · Cited by 11
“Therefore, antagonism of CXCR2 has been demonstrated to work in combination with traditional chemotherapeutic agents in decreasing cellular senescence and malignancy, primarily through a decrease in MDSC tumor infiltration [189].”
BackgroundThe potential of targeting Sin3B and its associated complexes for cancer therapy
Cantor, D. J., & David, G. (2017) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2017.1386655 · Cited by 11
“In contrast, enhancing senescence and the SASP in PCa sensitizes prostate cancer cells to cytotoxic therapies and improves survival in mice [94, 95, 96].”
BackgroundInflammatory profiles revealed the dysregulation of cytokines in adult patients of HFMD
Yu, L., He, J., Wang, L., & Yi, H. (2018) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2018.11.001 · Cited by 10
Maxwell, P. J., McKechnie, M., Armstrong, C. W., Manley, J. M., Ong, C. W., Worthington, J., Mills, I. G., Longley, D. B., Quigley, J. P., Zoubeidi, A., et al. (2022) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-21-0780 · Cited by 11
“For example, CXCR2 signaling promotes the infiltration of myeloid-derived suppressor cells (28) and preferentially sustains pro-tumorigenic M2-differentiation of tumor-resident macrophages within the TME of murine PTEN-deficient prostate cancer’s (29).”
BackgroundCotarelo, C., Schad, A., Schmidt, M., Hönig, A., Sleeman, J. P., & Thaler, S. (2023) · Cancers · doi:10.3390/cancers15061860 · Cited by 10
“Furthermore, tumor-infiltrating immune cells can counter senescence through non-cell autonomous mechanisms that protect proliferating tumor cells from senescence or enable already arrested cells to escape from oncogene-induced senescence, thus sustaining tumor growth [19].”
BackgroundInfluentialPan, Q., Ye, Z., Ye, Z., Zhang, H., Wang, J., Yi, G., Li, Z., Xu, R., Wang, L., Wu, Z., et al. (2025) · BMEMat · doi:10.1002/bmm2.12137 · Cited by 11
Tumor-infiltrating myeloid cells drive senescence evasion and chemoresistance in tumors
Mitri, D. D., Toso, A., & Alimonti, A. (2015) · OncoImmunology · doi:10.4161/2162402x.2014.988473 · Cited by 9
“Notably, IL-1a signaling was strongly enhanced in the tumor context and peritoneal administration of IL-1a in mice was shown to powerfully potentiate the senescence response in the prostatic epithelia, thus confirming the pro-senescence potential of this cytokine in such a genetic background.(9) Importantly, our study…”
BackgroundSelf-citationPreclinical and Coclinical Studies in Prostate Cancer
Chen, M., & Pandolfi, P. P. (2017) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a030544 · Cited by 10
“A recent study has also shown that a population of CD11b+Gr1+myeloid cells from the innate immune system protect a fraction of proliferating Pten-null mouse prostate tumors from senescence, thus sustaining tumor growth (Di Mitri et al. 2014).”
BackgroundFan, G., Xie, T., Tan, Q., Lou, N., Wang, S., Han, X., & Shi, Y. (2023) · iScience · doi:10.1016/j.isci.2023.107894 · Cited by 9
Dai, Q., Wang, H., Li, F., Huang, R., Jiang, C., Yuan, L., Wang, Y., & Li, X. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1467357 · Cited by 8
The Interplay of Aging and Cancer: Mechanisms, Implications, and Therapeutic Strategies
Wang, L., Luo, Y., Chen, X., Wang, Y., & Zhang, Y. (2025) · MedComm – Oncology · doi:10.1002/mog2.70041 · Cited by 10
Mechanisms of Immune Evasion in PTEN Loss Prostate Cancer
Esteban-Villarrubia, J., Ballesteros, P. Á., Martín-Serrano, M., Vico, M. R., Funes, J. M., de Velasco, G., Castro, E., Olmos, D., Castellano, D., & González‐Billalabeitia, E. (2024) · Immuno · doi:10.3390/immuno4040028 · Cited by 10
To clear, or not to clear (senescent cells)? That is the question
Lujambio, A. (2016) · Inside the Cell · doi:10.1002/icl3.1046 · Cited by 11
Pervizou, D., Chiara, J. D., Spinelli, L., NESTOR-MARTIN, M., Chasson, L., LEN-TAYON, K., Yanushko, D., FIORE, F., Bajénoff, M., Malissen, B., et al. (2025) · OncoImmunology · doi:10.1080/2162402x.2025.2562220 · Cited by 7
Heart of the matter: Neutrophils, cancer, and cardiovascular disease
Ambreen, S., McCarthy, A., Hidalgo, A., & Adrover, J. M. (2025) · The Journal of Experimental Medicine · doi:10.1084/jem.20242402 · Cited by 8
Oyen, W. J. G., & Bono, J. S. D. (2016) · Journal of Nuclear Medicine · doi:10.2967/jnumed.116.179887 · Cited by 7
“because studies indicate that myeloid-derived suppressor cells, for example, can protect prostate cancer cells from anticancer agent cytotoxicity (9).”
BackgroundCombination CD200R/PD-1 blockade in a humanised mouse model
Fellermeyer, M., Anzilotti, C., Paluch, C., Cornall, R. J., Davis, S. J., & Gileadi, U. (2023) · Immunotherapy Advances · doi:10.1093/immadv/ltad006 · Cited by 7
“A great number of approaches are being utilised, including the use of immune-checkpoint inhibitors to trigger phagocytosis [2], or to induce the re-programming of myeloid-derived suppressor cells (MDSCs) and tumour-associated macrophages [3, 4].”
BackgroundTumor-associated neutrophils: a complex role in cancer
Gao, X., Xu, M., Xiao, H., Han, Z., Wang, Z.-T., Sun, G., Zhang, D., Shuangjian, Q., Ren, N., Zhou, C., et al. (2025) · Clinical Immunology · doi:10.1016/j.clim.2025.110558 · Cited by 7
Chen, Y., Liao, Y., Lam, L. M., He, L., Tsang, Y. S., Di, Y.-S., Liang, S.-T., & Xia, Q. H. (2020) · International Journal of Medical Sciences · doi:10.7150/ijms.46254 · Cited by 7
“Another study found that neutrophils can also promote tumor growth through converting senescent cancer cells into proliferating cancer cells via IL-1 receptor antagonist [24].”
BackgroundAdipocytes and Neutrophils Give a Helping Hand to Pancreatic Cancers
Bronte, V., & Tortora, G. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0682 · Cited by 7
Hijacking emergency granulopoiesis: Neutrophil ontogeny and reprogramming in cancer
Marinescu, G., & Feng, Y. (2026) · Molecular Oncology · doi:10.1002/1878-0261.70241 · Cited by 7
Immunological consequences of senescence in physiology and pathology
Zubova, A., Pietrocola, F., & Morsli, S. (2026) · Journal of Translational Medicine · doi:10.1186/s12967-026-08335-3 · Cited by 7
Kaya, T. A., Stein, K., Schaufler, A., Neyazi, B., Rashidi, A., Kahlert, U. D., Mawrin, C., Sandalcioglu, I. E., & Dumitru, C. A. (2024) · Journal of Leukocyte Biology · doi:10.1093/jleuko/qiae248 · Cited by 7
Nutritional Modulators of Cellular Senescence In Vitro
Provinciali, M., Pierpaoli, E., Piacenza, F., Giacconi, R., Costarelli, L., Basso, A., Recchioni, R., Marcheselli, F., Bray, D. H., Benlhassan, K., et al. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-801816-3.00022-4 · Cited by 8
Metadata
- Authors
- Di Mitri, D., Toso, A., Chen, J. J., Sarti, M., Pinton, S., Jost, T. R., D’Antuono, R., Montani, E., Garcia-Escudero, R., Guccini, I., Da Silva-Alvarez, S., Collado, M., Eisenberger, M., Zhang, Z., Catapano, C., Grassi, F., & Alimonti, A.
- Affiliations
- Institute of Oncology Research (CH)
- Institute for Research in Biomedicine (CH)
- Complejo Hospitalario Universitario de Santiago (ES)
- Johns Hopkins University (US)
- University of Milan (IT)
- Corresponding author
- Alimonti, Andrea
- ORCID
- Venue
- Nature
- Published
- 2014-08-24
- Volume
- 515
- Issue
- 7525
- Pages
- 134-137
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W1968545383
- Cited by
- 388
- References
- 32
- Citations by year
- 2026: 25 · 2025: 41 · 2024: 31 · 2023: 39 · 2022: 35 · 2021: 32 · 2020: 44 · 2019: 22 · 2018: 33 · 2017: 30 · 2016: 26 · 2015: 23 · 2014: 3
- FWCI
- 18.22
- Type
- journal article
- Language
- en
- Open access
- green
- hdl.handle.net
- Licence
- other-oa
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- IRIS (submittedVersion)
- RUNA. Repositorio Institucional del Sergas (Servicio Gallego de Salud (SERGAS)) (submittedVersion, other-oa)
- SERVAL (Université de Lausanne) (submittedVersion)
- Padua Research Archive (University of Padova) (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Telomeres, Telomerase, and Senescence
- Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Aging › Genetics, Aging, and Longevity in Model Organisms
- Keywords
- cellular senescence, senescence evasion, interleukin-1 receptor antagonist, senescence-associated secretory phenotype, chemoresistance, docetaxel, CXCR2 antagonist, innate immunity, tumor microenvironment
- MeSH terms
- Docetaxel, Animals, Cell Movement, Humans, Immunity, Innate, Male, Prostatic Neoplasms, Cellular Senescence, Disease Progression, Drug Resistance, Neoplasm, Tumor Escape, Receptors, Chemokine, Myeloid Cells, Receptors, Interleukin-8B, Taxoids, PTEN Phosphohydrolase, Mice, Interleukin-1alpha, Interleukin 1 Receptor Antagonist Protein, Tumor Microenvironment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.